Pfizer posts Phase 3 data for Lyme vaccine candidate LB6V at IDWeek 2026
Pfizer flagged Phase 3 results for its LB6V Lyme disease vaccine candidate, with IDWeek 2026 presentations scheduled Oct. 22. The readout supported the shot’s ability to protect against Lyme disease, strengthening its case as a potential new commercial vaccine entrant. Regulatory momentum advanced in Europe, with the E